{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T05:15:46Z","timestamp":1794719746163,"version":"4.9.1"},"reference-count":72,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["Awarded to KB as a NIHR Clinical Lecturer"],"award-info":[{"award-number":["Awarded to KB as a NIHR Clinical Lecturer"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["MDR funded on a Doctoral Fellowship (NIHR300967)."],"award-info":[{"award-number":["MDR funded on a Doctoral Fellowship (NIHR300967)."]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Anterior uveitis is a common extra\u2010articular manifestation of axial spondyloarthritis (AxSpA). We set to evaluate the risk of anterior uveitis (AU) with biologics and synthetic disease\u2010modifying drugs in AxSpA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a systematic review and meta\u2010analysis to identify phase II\/III double\u2010blinded randomized controlled trials of anti\u2013tumor necrosis factor (TNF) monoclonal antibodies (mAb), anti\u2013interleukin\u201017 (anti\u2013IL\u201017), and Janus kinase inhibitors (JAKi) in AxSpA. Patient\u2010exposure years (PEY) were calculated using the per\u2010protocol approach. Incidence rate (IR) of AU\/100 person\u2010years were calculated by treatment group using the random effects approach. Network meta\u2010analysis (NMA) was used to estimate risk of AU in treatment groups, expressed as IR ratios (IRRs). Bias was assessed using the Cochrane Risk of Bias\u20102 tool.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty\u2010four trials were included: 17 anti\u2010TNF mAb (1,004 PEY), 9 etanercept (180 PEY), 13 anti\u2013IL\u201017 (1,834 PEY), and 6 JAKi (331 PEY). The IR of AU were as follows for anti\u2010TNF mAb: 4.1, 95% confidence interval (CI) 0\u20138.5; etanercept: 5.4, 95% CI 0\u201316.0; anti\u2013IL\u201017: 2.8, 95% CI 1.6\u20134.1; JAKi: 1.5, 95% CI 0.0\u20133.0; and placebo: 10.8, 95% CI 7.4\u201314.1. In NMA, IRRs of treatments compared with placebo were as follows for anti\u2010TNF mAb: 0.32, 95% CI 0.10\u20131.04; etanercept 0.42, 95% CI 0.08\u20132.38; anti\u2013IL\u201017: 0.43, 95% CI 0.19\u20130.98; and JAKi: 0.32, 95% CI 0.06\u20131.67. Comparisons between anti\u2010TNF mAb, anti\u2013IL\u201017, and JAKi did not demonstrate any significant difference in AU risk. Using the surface under the cumulative ranking curve approach to rank AU risk, anti\u2010TNF mAbs were associated with the lowest risk followed by JAKi, anti\u2013IL\u201017, and etanercept. All treatments were ranked superior to placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Anti\u2010TNF mAbs, JAKi, and anti\u2013IL\u201017 appear protective against AU events in individuals with AxSpA, with no significant differences in risk of AU between treatments.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.42788","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T04:46:33Z","timestamp":1703047593000},"page":"704-714","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Incidence of Uveitis in Patients With Axial Spondylarthritis Treated With Biologics or Targeted Synthetics: A Systematic Review and Network <scp>Meta\u2010Analysis<\/scp>"],"prefix":"10.1002","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7552-0463","authenticated-orcid":false,"given":"Katie","family":"Bechman","sequence":"first","affiliation":[{"name":"King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijing","family":"Yang","sequence":"additional","affiliation":[{"name":"King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5560-6603","authenticated-orcid":false,"given":"Maryam","family":"Adas","sequence":"additional","affiliation":[{"name":"King's College London, London, United Kingdom, and University of Jeddah  Jeddah Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Nagra","sequence":"additional","affiliation":[{"name":"King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"S. U\u011fuzlar","sequence":"additional","affiliation":[{"name":"King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8171-7772","authenticated-orcid":false,"given":"Mark D.","family":"Russell","sequence":"additional","affiliation":[{"name":"King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicky","family":"Wilson","sequence":"additional","affiliation":[{"name":"King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Steer","sequence":"additional","affiliation":[{"name":"King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1714-9963","authenticated-orcid":false,"given":"Sam","family":"Norton","sequence":"additional","affiliation":[{"name":"King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Galloway","sequence":"additional","affiliation":[{"name":"King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001108"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.075754"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1093-z"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31339-3"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.040"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.969368"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.052092"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210931"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220420"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02549-0"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"issue":"1","key":"e_1_2_6_15_1","article-title":"Revised Cochrane risk of bias tool for randomized trials (RoB 2.0): additional considerations for cluster\u2010randomized trials","volume":"10","author":"Eldridge S","year":"2016","journal-title":"Cochrane Methods Cochrane Database Syst Rev"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-016-1583-7"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21913"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201766"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202533"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23606"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204231"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40866"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23969"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170487"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39257"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu132"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20852"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24408"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091042"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.022582"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203201"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08215-6"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012664"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11325"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11017"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020875"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.056747"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.121327"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.139261"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38721"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-014-0481-5"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40753"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31946-9"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32971-X"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61134-4"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1490-y"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-018-0123-5"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41477"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001099"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223595"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216980"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219601"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210322"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32534-6"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01212-0"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222608"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32463-2"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez449"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.01.009"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.01.006"},{"issue":"7","key":"e_1_2_6_62_1","first-page":"2678","article-title":"A phase 2 randomized controlled trial of the Janus kinase (JAK) inhibitor filgotinib in patients with noninfectious uveitis","volume":"63","author":"Srivastava SK","year":"2022","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2022.2069128"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04875-w"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05651-5"},{"key":"e_1_2_6_66_1","first-page":"641","article-title":"Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells","volume":"26","author":"Bing SJ","year":"2020","journal-title":"Mol Vis"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001107"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.12.033"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1585"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.06.022"},{"key":"e_1_2_6_71_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.156"},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42280"},{"key":"e_1_2_6_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02303-0"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.42788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:27:35Z","timestamp":1759940855000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.42788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,13]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1002\/art.42788"],"URL":"https:\/\/doi.org\/10.1002\/art.42788","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,13]]},"assertion":[{"value":"2023-09-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}